Drug
Sonelokimab clinical trials
Also written M1095.
- studies test it
- 12
- open now
- 2
- in phase 3
- 7
- first study started
- 2014
Keep track of what changes. Save the sonelokimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
12 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2018 | 1 |
| 2022 | 2 |
| 2024 | 5 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 3
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
MoonLake Immunotherapeutics AG (10) · Bond Avillion 2 Development LP (1) · Merck KGaA, Darmstadt, Germany (1)
Studies
Open first, then newest update. How each study uses sonelokimab is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic ArthritisEnrolling by invitationPhase 3MoonLake Immunotherapeutics AGNCT07223138Written as Sonelokimab
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaEnrolling by invitationPhase 3MoonLake Immunotherapeutics AGNCT07007637Written as Sonelokimab
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseActive, not recruitingPhase 3MoonLake Immunotherapeutics AGNCT06641089Written as Sonelokimab
- Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugActive, not recruitingPhase 3MoonLake Immunotherapeutics AGNCT06641076Written as Sonelokimab
- Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisCompletedPhase 2MoonLake Immunotherapeutics AGNCT05640245Written as Sonelokimab
- Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaCompletedPhase 2MoonLake Immunotherapeutics AGNCT05322473Written as Sonelokimab (M1095)
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 3MoonLake Immunotherapeutics AGNCT06411899Written as Sonelokimab
- Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 3MoonLake Immunotherapeutics AGNCT06411379Written as Sonelokimab
- An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)Active, not recruitingPhase 3MoonLake Immunotherapeutics AGNCT06768671Written as Sonelokimab
- An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an AutoinjectorCompletedPhase 1MoonLake Immunotherapeutics AGNCT06994936Written as Sonelokimab
- A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe PsoriasisCompletedPhase 2Bond Avillion 2 Development LPNCT03384745Written as M1095 (Sonelokimab)
- Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis SubjectsCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT02156466Written as MSB0010841
Codes
What other systems call sonelokimab · ClinicalTrials.gg INT001785
- MeSH (NLM) C000720946sonelokimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) LEN0OCZ4SHSONELOKIMABConfirmed FDA, NLM
- NCI Thesaurus C171838SonelokimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720946 | sonelokimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | LEN0OCZ4SH | SONELOKIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C171838 | Sonelokimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.